
Cogint (COGT) Stock Forecast & Price Target
Cogint (COGT) Analyst Ratings
Bulls say
Cogent Biosciences Inc. is on track for a potentially significant year in 2025, with expectations of becoming an appealing target for mergers and acquisitions, particularly if the outcomes of the APEX and PEAK trials are favorable. The company's valuation has been positively adjusted, reflecting an increased probability of approval for its drug combination treatment in advanced gastrointestinal stromal tumors (GIST), alongside a notable rise in expected market penetration rates. Additionally, the impressive overall response rates observed across multiple clinical trials—including the SUMMIT trial—suggest that the therapy bezuclastinib may have a robust competitive standing in the treatment landscape for various malignancies.
Bears say
Cogent Biosciences is projected to experience a substantial net loss of $2.28 per share for the entirety of 2025, indicating ongoing financial challenges. A number of risks contribute to this negative outlook, including the possibility of adverse clinical data for key drugs, delays in development timelines, and potential setbacks in obtaining regulatory approvals. Additionally, concerns surrounding commercial success and the risk of long-term dilution further exacerbate the company’s financial vulnerabilities.
This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.
Cogint (COGT) Analyst Forecast & Price Prediction
Start investing in Cogint (COGT)
Order type
Buy in
Order amount
Est. shares
0 shares